RARE CANCEREye CancerWHO 5th Edition Classification

Retinoblastoma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

The commonest eye cancer of childhood, caused by loss of both copies of the RB1 tumour suppressor gene. Roughly 40% of cases are heritable, usually bilateral and diagnosed earlier, and carry a lifelong increased risk of second cancers. It is one of the most curable childhood cancers when diagnosed early - and one of the most lethal when diagnosis is late, which is why survival differs so sharply between countries.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • White pupillary reflex at any age - same-week ophthalmology referral
  • Heritable disease requires lifelong surveillance for second malignancies
Who It Affects

Infants and young children, usually diagnosed under 5; bilateral disease presents earlier

Annual Incidence

Approximately 1 in 15,000-20,000 live births

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

A white reflection in the pupil, often first noticed in a photograph (leukocoria)
A newly turned or squinting eye (strabismus)
A red, painful or swollen eye
Poor vision or a change in iris colour
A visibly enlarging eye in advanced disease

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

RB1 biallelic inactivationGermline RB1 in about 40%MYCN amplification in a rare RB1-wild-type subset

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Systemic chemotherapy to shrink tumours (chemoreduction) followed by focal therapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Intra-arterial chemotherapy delivered via the ophthalmic artery

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Intravitreal chemotherapy for vitreous seeding

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Focal consolidation with laser photocoagulation or cryotherapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Plaque brachytherapy or, less often, external beam radiotherapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Enucleation for advanced unilateral disease - still curative and sometimes the right choice

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

7

Germline RB1 testing for the child and screening of siblings

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Survival exceeds 95% in high-income countries where disease is caught while intraocular. It remains substantially lower in settings where children present with extraocular extension - which is a health-system problem rather than a biological one. Eye and vision preservation depend on stage at presentation.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Refinement of intra-arterial and intravitreal delivery to preserve vision, and global initiatives to reduce diagnostic delay in low- and middle-income settings, are the two most consequential areas of work.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Retinoblastoma

Browse All Oncologists

Dr. Jesse L. Berry

Ocular Oncologist

10+ yrs exp

Children's Hospital LA

Los Angeles, USA

Ocular OncologyRetinoblastomaIntra-arterial Chemotherapy
Vetted DirectoryConsult Specialist

Dr. Audrey Chia

Senior Pediatric Ophthalmologist

20+ yrs exp

SNEC

Singapore, Singapore

Pediatric OphthalmologyRetinoblastomaChemoreduction
Vetted DirectoryConsult Specialist

Prof. David H. Abramson

Ocular Oncologist

40+ yrs exp

MSKCC

New York, USA

Ocular OncologyRetinoblastomaLocal Therapies
Vetted DirectoryConsult Specialist

Dr. Bikramjit Pal

Ocular Oncologist

15+ yrs exp

Sankara Nethralaya

Chennai, India

Ocular OncologyRetinoblastomaGlobe-conserving Treatment
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Ewing Sarcoma

rare

Osteosarcoma

Independent Tumor Board Review

Facing a Diagnosis of Retinoblastoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult